Home · Health · Sep 7 archive
Fake Weight-Loss Drug Puts Patients at Risk as Industry Booms
Confirmed
In Short: Experts warn of a surge in counterfeit versions of an experimental weight-loss drug, retatrutide, raising concerns about patient safety and regulatory challenges.
Experts have told the BBC that this is one of the first instances where copycat versions of an experimental drug, still in clinical trials, have become so widely available. The high demand for a new weight-loss drug, especially one showing early promise, has led to the proliferation of fake versions, causing a headache for both the pharmaceutical company and regulators.
Tom, a trial participant, accidentally took eight times the recommended dose of a fake version of retatrutide and nearly ended up in the hospital, highlighting the potential dangers of these counterfeit drugs. Only 50% of drugs in this Phase III stage of testing in the US are eventually approved by the FDA, so there is no guarantee that retatrutide will ever hit the market.
The high rate of failure is primarily due to drugs not working as well in large, diverse human populations as they do in smaller early tests, or because they reveal unexpected safety hazards. This underscores the critical importance of rigorous testing and regulation.
At the Socialism 2026 conference in Chicago, an activist criticized the 'diet industry' for policing 'Black fat flesh,' characterizing modern health standards and weight management as forms of 'body fascism.' He also criticized GLP-1 weight-loss drugs like Ozempic, arguing that efforts to treat fatness as a public-health issue are intrinsically connected to racial control.
What's confirmed
What's still developing
- He says trial participants need to meet strict criteria before they are given the green light to start taking the real drug or a placebo.